$ANIX

Titterton Lewis H jr purchased 8,000 shares of Anixa Biosciences Inc (ANIX) at $2.98 on 2026-10-23.

Anixa Biosciences completed dosing for the fifth cohort in its Phase 1 CAR-T trial for ovarian cancer, reporting no dose-limiting toxicities and stable disease in the first patient. Four patients have survived over a year, one over two years. The trial is in early-stage safety and dose-escalation, with preliminary efficacy signals.

KUMAR AMIT (Chief Executive Officer) purchased 8,000 shares of Anixa Biosciences Inc (ANIX) at $2.72 on 2026-10-22.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

Anixa Biosciences (ANIX) President, COO & CFO Michael Catelani bought 5,500 shares on 2026-09-30, increasing his holdings to 50,000. The company has seen 18 insider buys and no sells in the past year. ANIX shares traded at $2.84, giving it a market cap of $100.99M. The company is a clinical-stage biotech focused on cancer treatments.

Catelani Michael (President, COO, & CFO) purchased 5,500 shares of Anixa Biosciences Inc (ANIX) at $2.84 on 2026-09-30.

Berkshire Hathaway bought Lennar (LEN) shares worth $136M. Insiders at Anixa (ANIX), DeFi (DFDV), Clipper (CLPR), and Harvard Apparatus (HRGN) made purchases. CrowdStrike (CRWD) CFO and Robinhood (HOOD) CEO sold shares worth $125M and $30M, respectively. Everpure (P) and Fastly (FSLY) insiders also sold shares.